VIM and autoimmune polyendocrinopathy: This leaves clinicians with 10 to 30% of non-criteria or “seronegative” APS (SN-APS) [160], where emerging literature identified further biomarkers that may hold both pathogenic relevance and diagnostic utility, such as the anti-phosphatidylserine/prothrombin complex (aPS/PT) IgG, anti-vimentin/cardiolipin complex (aVim/CL) IgG, and anti-carbamylated-β2-glycoprotein I (aCarb-β2-GPI) IgG, and aβ2-GPI-domain 1 [161].